1 / 17

Pharmacoepidemiology

Pharmacoepidemiology. Kristian B. Filion, PhD CIHR New Investigator Assistant Professor of Medicine Division of Clinical Epidemiology Lady Davis Institute for Medical Research Jewish General Hospital/McGill University. Definition.

ianna
Download Presentation

Pharmacoepidemiology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmacoepidemiology Kristian B. Filion, PhD CIHR New Investigator Assistant Professor of Medicine Division of Clinical Epidemiology Lady Davis Institute for Medical Research Jewish General Hospital/McGill University

  2. Definition Pharmacoepidemiology is the study of the use of and the effects of drugs in large numbers of people. The term pharmacoepidemiology obviously contains two components: “pharmaco” and “epidemiology”. Brian L. Storm (editor). Pharmacoepidemiology (fourth edition)

  3. Drug Safety and Effectiveness • Drug Safety: • Post-Marketing Surveillance of Adverse Drug Effects • Comparative Effectiveness Research: • Designed to inform health-care decisions by providing evidence on the effectiveness, benefits, and harms of different treatment options • Evidence is generated from research studies that compare drugs, medical devices, tests, surgeries, or ways to deliver health care http://effectivehealthcare.ahrq.gov/index.cfm/what-is-comparative-effectiveness-research1/

  4. Drug Safety and Effectiveness Network (DSEN) • Joint CIHR-Health Canada initiative ($32M over 5 years) • Part of the Food and Consumer Safety Action Plan • Key objectives: • Increase the available evidence on drug safety and effectiveness available to regulators, policy-makers, health care providers and patients • Increase capacity within Canada to undertake high-quality post-market research • Team grants: • Canadian Network for Observational Drug Effect Studies (CNODES) • Drug Safety and Effectiveness Network Collaborating Centre for Prospective Studies http://www.cihr-irsc.gc.ca/e/40269.html

  5. Potential Contributions of Pharmacoepidemiology • Information which supplements the information available from premarketing studies – better quantitation of the incidence of known adverse and beneficial effects • Higher precision • In patients not studied prior to marketing (e.g., the elderly, children, in pregnant women) • As modified by other drugs and other illnesses • Relative to other drugs used for the same indication Brian L. Storm (editor). Pharmacoepidemiology (fourth edition)

  6. Potential Contributions of Pharmacoepidemiology (Cont.) • New types of information not available from premarketing studies • Discovery of previously undetected adverse and beneficial effects (e.g., Uncommon effects, Delayed effects) • Patterns of drug utilization • The effects of drug overdoses • The economic implications of drug use • General contributions of pharmacoepidemiology • Reassurances about drug safety • Fulfillment of ethical and legal obligations Brian L. Storm (editor). Pharmacoepidemiology (fourth edition)

  7. Dormandy et. al. Lancet 2005.

  8. Bladder Cancer in PROACTIVE * Cases remaining after blinded review Dormandy et. al. Lancet 2005.

  9. Azoulay et. al. BMJ 2012.

  10. Thiazolidinediones and Risk of Bladder Cancer *Matched on year of birth, year of cohort entry, sex, and duration of follow-up. †Adjusted for excessive alcohol use, obesity, smoking status, HbA1c , previous bladder conditions, previous cancer (other then non-melanoma skin cancer), Charlson comorbidity score, and ever use of other antidiabetic agents (metformin, sulfonylureas, insulin, and other oral hypoglycaemic agents). Azoulay et. al. BMJ 2012.

  11. Other Examples of Pharmacoepidemiology at McGill

  12. Other Examples of Pharmacoepidemiology at McGill

  13. Other Examples of Pharmacoepidemiology at McGill International Psychogeriatrics Assessing the cumulative effects of exposure to selected benzodiazepines on the risk of fall-related injuries in the elderly Marie-Pierre Sylvestre, Michal Abrahamowicz, RadanČapek and Robyn Tamblyn

  14. Other Examples of Pharmacoepidemiology at McGill

  15. Pharmacoepidemiology Investigators at McGill • Laurent Azoulay • SachaBernatsky • Jean-François Boivin • Paul Brassard • James Brophy • Jaimie Caro • Pierre Ernst • Kristian Filion • ElhamRahme • Michel Rossignol • Samy Suissa • Vicky Tagalakis • Robyn Tamblyn

  16. ProspectiveJobs • Academia • Government • Consulting • Pharmaceutical Industry

  17. THANK YOU!Kristian.filion@mcgill.ca

More Related